文档介绍：罗格列酮治疗2型糖尿病合并脂肪肝的临床观察
作者:刘同刚沙凯辉张丽张蕾
【摘要】目的临床观察胰岛素增敏剂罗格列酮对2型糖尿病合并脂肪肝患者治疗的有效性和安全性。方法分析31例2型糖尿病合并脂肪肝患者应用罗格列酮治疗前后血常规、血糖、血脂、空腹胰岛素、糖化血红蛋白、体重、血压、肝功、肾功、C反应蛋白、肝脏B超、尿常规等变化及不良反应。结果治疗后空腹血糖、糖化血红蛋白、血TG、C反应蛋白水平较治疗前有显著下降,胰岛素敏感性明显上升。复查肝脏B超提示8例患者脂肪肝消失。监测肾功能、血尿常规、心电图等均无异常变化。治疗过程中出现双下肢浮肿4例,继续观察1~2周或适当加用利尿剂后消退;无明显胃肠道反应、低血糖反应等。结论罗格列酮降糖效果确切,并有一定降压、调脂的作用,使肝内脂肪浸润减少,副反应轻微,对2型糖尿病合并脂肪肝患者有良好的疗效及安全性。
【关键词】罗格列酮;糖尿病,非胰岛素依赖型;脂肪肝
【Abstract】 Objective To evaluate the clinical efficacy and safety of rosiglitazone for treatment of type 2 diabetics with fatty liver. Methods The fasting plasma glucose (FPG), lipids, fasting insulin, HbA1c, blood pressure , CRP, liver function , renal function and Bmode ultrasonography of liver were analysed before and after treatment of rosiglitazone in 31 type 2 diabetic patients with fatty liver At the same time, the adverse effects of rosiglitazone in the treatment of type 2 diabetics with fatty liver were The results showed th
at rosiglitazone reduced FPG, TG , CRP, and HbA1c levels respectively. The mean levels of ALT were reduced slightly after treatment. The result of backchecked Bmode ultrasonography of liver showed the image of fatty liver disappeared in 8 patients after treatment. The renal function, ECG and routine examination of blood and urine had no apparent changes after treatment .The edema of lower limb which was occurred in patients in th